The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Safety and Effectiveness Study of an Experimental Topical Ointment (GS-9191) for the Treatment of Genital Warts
Official Title: A Phase 1, Randomized, Double-Blind, Placebo-Controlled Assessment of the Safety, Tolerability, and Activity of GS-9191 Ointment for the Treatment of External Genital and Perianal Warts Caused by Human Papilloma Virus Infection
Study ID: NCT00499967
Brief Summary: The purpose of this study is to assess the safety, tolerability and activity of GS-9191 ointment in the treatment of genital warts. GS-9191 ointment is intended for topical application directly to genital warts on the skin.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT
Sex: ALL
Healthy Volunteers: No
, Tucson, Arizona, United States
, Beverly Hills, California, United States
, Mission Viejo, California, United States
, San Fransisco, California, United States
, San Fransisco, California, United States
, Santa Rosa, California, United States
, Vallejo, California, United States
, Orlando, Florida, United States
, Tampa, Florida, United States
, Indianapolis, Indiana, United States
, St. Louis, Missouri, United States
, Las Vegas, Nevada, United States
, New York, New York, United States
, Stony Brook, New York, United States
, Raleigh, North Carolina, United States
, Tulsa, Oklahoma, United States
, Portland, Oregon, United States
, Greenville, South Carolina, United States
, Chattanooga, Tennessee, United States
, Dallas, Texas, United States
, Houston, Texas, United States
, San Antonio, Texas, United States
, San Antonio, Texas, United States
, Salt Lake City, Utah, United States
, Seattle, Washington, United States
Name: Elsa Mondou, MD
Affiliation: Gilead Sciences
Role: STUDY_DIRECTOR